SAN DIEGO, Feb. 2, 2021 /PRNewswire/ -- Viriom Inc (Viriom) announces that its antiviral drug Elpida®(elsulfavirine) has been included in the preferred first-line antiretroviral therapy (ART) regimens by the Ministry of Health of the Russian Federation according to updated clinical guidelines for the treatment of HIV infection in adults and children. Regimens for adults include the combination of elsulfavirine + lamivudine (or emtricitabine) + tenofovir. Viriom has filed for the market authorization of the fixed dose combination of elsulfavirine + tenofovir and emtricitabine in Russia and the Eurasian Economic Union.
SAN DIEGO, April 8, 2020 /PRNewswire/ -- Viriom, Inc. today announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19 (novel coronavirus). This randomized, open-label, multicenter study will enroll approximately 240 patients at medical centers primarily across Russia and EAEU countries, as well as other countries globally with high numbers of diagnosed cases, beginning in May. The study will assess two doses of elsulfavirine, administered as oral tablets. Elsulfavirine is marketed in Russia and EAEU countries for the treatment of HIV infection. The new clinical study expands the ongoing research into elsulfavirine, which includes confirmation of elsulfavirine antiviral activity against COVID-19 infection by the State Key Laboratory of Diagnosis and Treatment of Infectious Diseases, Zhejiang University in China.
Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Viriom, Inc. (San Diego, CA) announced today that it has initiated the first Phase 1 clinical trial of the long acting nanoformulation of VM1500A in HIV-uninfected volunteers. This trial is designed to evaluate the safety and pharmacokinetics of VM1500A once monthly dosing in up to 36 HIV-uninfected volunteers in a single site clinical trial in Moscow, Russia.